Balyasny Asset Management’s Evolent Health EVH Stock Holding History

Balyasny Asset Management’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-100,000	Closed	-$3.07M	–	2948
2022 Q2	$3.07M	Buy	+100,000	New	+$2.91M	0.01%	1167
2022 Q1	–	Sell	-113,900	Closed	-$3.15M	–	2575
2021 Q4	$3.15M	Buy	113,900 +13,900	+14%	+$399K	0.01%	1017
2021 Q3	$3.1M	Buy	+100,000	New	+$2.4M	0.01%	980
2020 Q4	–	Sell	-50,000	Closed	-$621K	–	1433
2020 Q3	$621K	Buy	+50,000	New	+$588K	﹤0.01%	1072

Other funds holding EVH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's EVH Position: Q1 2026 in Review

Balyasny Asset Management reduced its Evolent Health (EVH) stake by 70% in Q1 2026, selling an estimated $2.79M and leaving 381,749 shares worth $870K. The position accounts for ﹤0.01% of the portfolio, ranked #2138.

Balyasny Asset Management first reported a position in EVH in Q4 2017 and has held it in 19 quarters since. The position peaked at $13.6M in Q3 2023. 191 funds tracked by Wall St. Rank hold EVH as of Q1 2026.

Balyasny Asset Management held 381,749 shares of Evolent Health worth $870K as of Q1 2026.
Balyasny Asset Management sold 879,258 Evolent Health shares in Q1 2026, an estimated $2.79M.
Evolent Health made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2138 holding.
Balyasny Asset Management first reported a position in Evolent Health in Q4 2017 and has held it in 19 quarters since.
Balyasny Asset Management's Evolent Health position peaked at $13.6M in Q3 2023.
191 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.